Epirium Bio Completes Dosing in First-In-Human Phase 1 Clinical Trial Evaluating MF-300, A First-In-Class, Oral 15-PGDH Enzyme Inhibitor, For the Treatment of Sarcopenia
Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced the completion of dosing in its Phase 1 trial. The randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) trial was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of MF-300 in healthy adults. MF-300 is an investigational, first-in-class, orally administered, 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor currently in development for the treatment of sarcopenia, or age-related muscle weakness. Preliminary data indicate all adverse events were considered mild to moderate, with no severe or serious adverse events reported. Further, there were no early discontinuations, and no stopping criteria were met.
Epirium Bio Announces First Participants Dosed in Phase 1 Clinical Trial in Healthy Volunteers, Evaluating MF-300, a First-In-Class, Oral 15-PGDH Enzyme Inhibitor, for the Treatment of Sarcopenia
Epirium Bio, Inc. (Epirium), a biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced that it has initiated dosing of healthy volunteers in its Phase 1 dose-escalation clinical trial of MF-300, an investigational, first-in-class, orally administered,15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor in development for the treatment of sarcopenia, or age-induced muscle weakness.
